Register
Forgot your password?

Cardio-oncological continuum: clinical and pathogenetic relationships and choice of optimal treatment strategies for coronary heart disease

Company: Kozlova O.S.1, Slivneva I.V.,1 Pylev A.L.2, Petrosyan K.V.,1 Golukhova E.Z.1

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2026-20-1-26-36

For citation: Kozlova O.S., Slivneva I.V., Pylev A.L., Petrosyan K.V., Golukhova E.Z. Cardio-oncological continuum: clinical and pathogenetic relationships and choice of optimal treatment strategies for coronary heart disease. Creative Cardiology. 2026; 20 (1): 26–36 (in Russ.). DOI: 10.24022/1997-3187-2026-20-1-26-36

Received / Accepted:  22.01.2026 / 16.02.2026

Keywords: сoronary heart disease cancer myocardial revascularization



Subscribe 🔒

 

Abstract

Understanding the complex interaction between coronary heart disease (CHD) and cancer is fundamental to selecting optimal treatment strategies and improving survival rates. Our review presents new risk factors and analyzes the pathogenetic mechanisms of mutually aggravating diseases.

Algorithms for surgical interventions in patients with CHD and malignant neoplasms are currently not defined. The balance of risks and benefits may depend not only on the indications for surgical revascularization and the complexity of the coronary lesion, but also on the risk of bleeding, thrombosis, and the overall prognosis of cancer. A review of perioperative and long-term results of treatment of CHD in a complex category of patients will help practicing physicians to decide on the possibility of myocardial revascularization even in disseminated cancer patients. However, further fundamental clinical research is needed to improve diagnostic and therapeutic approaches.

References

  1. Xue P., Lin L., Li P. et al. Global, regional, and national epidemiology of ischemic heart disease among individuals aged 55 and above from 1990 to 2021: a cross-sectional study. BMC Public. Health. 2025; 25 (1): 985. DOI: 10.1186/s12889-025-22193-6
  2. Shi H., Xia Y., Cheng Y. et al. Global burden of ischemic heart disease from 2022 to 2050: projections of incidence, prevalence, deaths, and disability – adjusted life years. Eur. Heart J. Qual. Care Clin. Outcomes. 2024. DOI: 10.1093/ehjqcco/qcae049
  3. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024; 74 (3): 229–263. DOI: 10.3322/caac.21834
  4. Condurache D.G., Raisi-Estabragh Z., Ghosh A.K., Mamas M.A. Ischemic heart disease in the cancer population: trends, outcomes, epidemiology, and challenges in diagnosis and treatment. Cardiol. Clin. 2025; 43 (1): 57–67. DOI: 10.1016/j.ccl.2024.08.001
  5. Dai L., Li R., Hao Q. et al. Breast cancer is associated with coronary heart disease: a cross-sectional survey of NHANES 1999–2018. Front. Cardiovasc. Med. 2023; 10: 1274976. DOI: 10.3389/fcvm.2023.1274976
  6. Suzuki M., Tomoike H., Dai Z. et al. Polyvascular disease and the incidence of cancer in patients with coronary artery disease. JMAJ. 2022; 5 (4): 498–509. DOI: 10.31662/jmaj.2022-0098
  7. Velusamy R., Nolan M., Murphy A. et al. Screening for coronary artery disease in cancer survivors: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2023; 5 (1): 22–38. DOI: 10.1016/j.jaccao.2022.12.007
  8. Golukhova E.Z., Slivneva I.V., Pylev A.L. et al. Optimal treatment strategies for coronary heart disease in cancer patients: a complex clinical case. Monaldi Arch. Chest. Dis. 2025; 95: 3149. DOI: 10.4081/monaldi.2024.3149
  9. Ueki Y., Vögeli B., Karagiannis A. et al. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol. 2019; 1 (2): 145–155. DOI: 10.1016/j.jaccao.2019.11.001
  10. Ameri P., Bertero E., Lombardi M. et al. Ischaemic heart disease in patients with cancer. Eur. Heart J. 2024; 45 (14): 1209–1223. DOI: 10.1093/eurheartj/ehae047
  11. Lau E.S., Paniagua S.M., Liu E. et al. Cardiovascular risk factors are associated with future cancer. JACC CardioOncol. 2021; 3 (1): 48–58. DOI: 10.1016/j.jaccao.2020.12.003
  12. Boudoulas K.D., Triposkiadis F., Gumina R. et al. Cardiovascular disease, cancer, and multimorbidity interactions: clinical implications. Cardiology. 2022; 147 (2): 196–206. DOI: 10.1159/000521680
  13. Kumar M., Yan P., Kuchel G.A., Xu M. Cellular senescence as a targetable risk factor for cardiovascular diseases: therapeutic implications: JACC family series. JACC Basic. Transl. Sci. 2024; 9 (4): 522–534. DOI: 10.1016/j.jacbts.2023.12.003
  14. Wilcox N.S., Amit U., Reibel J.B. et al. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat. Rev. Cardiol. 2024; 21 (9): 617–631. DOI: 10.1038/s41569-024-01017-x
  15. Mili N., Paschou S.A., Goulis D.G. et al. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021; 74 (3): 478–497. DOI: 10.1007/s12020-021-02884-x
  16. Katsi V., Papakonstantinou I., Tsioufis K. Atherosclerosis, diabetes mellitus, and cancer: common epidemiology, shared mechanisms, and future management. Int. J. Mol. Sci. 2023; 24 (14): 11786. DOI: 10.3390/ijms241411786
  17. Newman A.A.C., Dalman J.M., Moore K.J. Cardiovascular disease and cancer: a dangerous liaison. Arterioscler. Thromb. Vasc. Biol. 2025; 45 (3): 359–371. DOI: 10.1161/ATVBAHA.124.319863
  18. Murphy N., Song M., Papadimitriou N. et al. Associations between glycemic traits and colorectal cancer: a mendelian randomization analysis. J. Natl. Cancer Inst. 2022; 114 (5): 740–752. DOI: 10.1093/jnci/djac011
  19. Byrne F.L., Martin A.R., Kosasih M. et al. The role of hyperglycemia in endometrial cancer pathogenesis. Cancers (Basel). 2020; 12 (5): 1191. DOI: 10.3390/cancers12051191
  20. Zmaili M., Alzubi J., Alkhayyat M. et al. Cancer and cardiovascular disease: the conjoined twins. Cancers (Basel). 2024; 16 (8): 1450. DOI: 10.3390/cancers16081450
  21. Azab M., Al-Shudifat A.E., Johannessen A. et al. Are risk factors for coronary artery disease different in persons with and without obesity? Metab. Syndr. Relat. Disord. 2018; 16 (8): 440–445. DOI: 10.1089/met.2017.0152
  22. Soltani S., Abdollahi S., Aune D., Jayedi A. Body mass index and cancer risk in patients with type 2 diabetes: a dose-response meta-analysis of cohort studies. Sci. Rep. 2021; 11 (1): 2479. DOI: 10.1038/s41598-021-81671-0
  23. De Wit S., Glen C., de Boer R.A., Lang N.N. Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. Cardiovasc. Res. 2023; 118 (18): 3451–3466. DOI: 10.1093/cvr/cvac132
  24. Garcia-Ruiz C., Conde de la Rosa L., Ribas V., Fernandez-Checa J.C. Mitochondrial cholesterol and cancer. Semin. Cancer Biol. 2021; 73: 76–85. DOI: 10.1016/j.semcancer.2020.07.014
  25. Volpe M., Gallo G. Hypertension, coronary artery disease and myocardial ischemic syndromes. Vascul. Pharmacol. 2023; 153: 107230. DOI: 10.1016/j.vph.2023.107230
  26. Buziashvili Yu.I., Matskeplishvili S.T., Asymbekova E.U. (Eds.) Cardio-oncology – current issues. Moscow; 2025 (in Russ.).
  27. Blaes A., Prizment A., Koene R.J., Konety S. Cardio-oncology related to heart failure: common risk factors between cancer and cardiovascular disease. Heart Fail. Clin. 2017; 13 (2): 367–380. DOI: 10.1016/j.hfc.2016.12.006
  28. Sun H., Li T., Zhuang R. et al. Do renin-angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? Evidence from a meta-analysis including 55 studies. Medicine (Baltimore). 2017; 96 (13): 6394. DOI: 10.1097/MD.0000000000006394
  29. Sleptsov A.A., Nazarenko M.S., Puzyrev V.P. Common in atherogenesis and carcinogenesis: clonal hematopoiesis. Russian Journal of Cardiology. 2023; 28 (10): 5511 (in Russ.). DOI: 10.15829/1560-4071-2023-5511
  30. Kandarakov O., Belyavsky A. Clonal hematopoiesis, cardiovascular diseases and hematopoietic stem cells. Int. J. Mol. Sci. 2020; 21 (21): 7902. DOI: 10.3390/ijms21217902
  31. Dmitrieva-Posocco O., Dzutsev A., Posocco D.F. et al. Cell-type-specific responses to interleukin-1 control microbial invasion and tumor-elicited inflammation in colorectal cancer. Immunity. 2019; 50 (1): 166–180. DOI: 10.1016/j.immuni.2018.11.015
  32. Al Samarraie A., Pichette M., Rousseau G. Role of the gut microbiome in the development of atherosclerotic cardiovascular disease. Int. J. Mol. Sci. 2023; 24 (6): 5420. DOI: 10.3390/ijms24065420
  33. Ivleva E.A., Grivennikov S.I. Microbiota-driven mechanisms at different stages of cancer development. Neoplasia. 2022; 32: 100829. DOI: 10.1016/j.neo.2022.100829
  34. Feng Z., Wang Y., Xu H. et al. Recent advances in bacterial therapeutics based on sense and response. Acta Pharm. Sin. B. 2023; 13 (3): 1014–1027. DOI: 10.1016/j.apsb.2022.09.015
  35. Zhao X.J., Bing X., Lei Q.Q. et al. Assessment of five-year relative survival of patients with endometrial cancer: a period analysis. World J. Oncol. 2024; 15 (5): 784–791. DOI: 10.14740/wjon1921
  36. Han X.J., Li J.Q., Khannanova Z., Li Y. Optimal management of coronary artery disease in cancer patients. Chronic. Dis. Transl. Med. 2020; 5 (4): 221–233. DOI: 10.1016/j.cdtm.2019.12.007
  37. Wang L., Zhang R., Yu L. et al. Aspirin use and common cancer risk: a meta-analysis of cohort studies and randomized controlled trials. Front. Oncol. 2021; 11: 690219. DOI: 10.3389/fonc.2021.690219
  38. Torresan S., Bortolot M., De Carlo E. et al. Matters of the heart: cardiotoxicity related to target therapy in oncogene-addicted non-small cell lung cancer. Int. J. Mol. Sci. 2025; 26 (2): 554. DOI: 10.3390/ijms26020554
  39. Carlos-Escalante J.A., de Jesús-Sánchez M., Rivas-Castro A. et al. The use of antihypertensive drugs as coadjuvant therapy in cancer. Front. Oncol. 2021; 11: 660943. DOI: 10.3389/fonc.2021.660943
  40. Maron D.J., Hochman J.S., Reynolds H.R. et al. Initial invasive or conservative strategy for stable coronary disease. N. Engl. J. Med. 2020; 382 (15): 1395–1407. DOI: 10.1056/NEJMoa1915922
  41. Hochman J.S., Anthopolos R., Reynolds H.R. et al. Ischemia-extend research group. Survival after invasive or conservative management of stable coronary disease. Circulation. 2023; 147 (1): 8–19. DOI: 10.1161/CIRCULATIONAHA.122.062714
  42. Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. 2023; 44 (18): 1621. DOI: 10.1093/eurheartj/ehad196
  43. Mamas M.A., Brown S.A., Sun L.Y. Coronary artery disease in patients with cancer: it’s always the small pieces that make the bigger picture. Mayo Clin. Proc. 2020; 95 (9): 1819–1821. DOI: 10.1016/j.mayocp.2020.07.006
  44. Lawton J.S., Tamis-Holland J.E., Bangalore S. et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: a report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145 (11): e772. DOI: 10.1161/CIR.0000000000001061
  45. Kwok C.S., Wong C.W., Kontopantelis E. et al. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur. Heart J. 2021; 42: 1019–1034. DOI: 10.1093/eurheartj/ehaa1032
  46. Mrotzek S.M., Lena A., Hadzibegovic S. et al. Assessment of coronary artery disease during hospitalization for cancer treatment. Clin. Res. Cardiol. 2021; 110 (2): 200–210. DOI: 10.1007/s00392-020-01719-5
  47. Guo W., Fan X., Lewis B.R. et al. Cancer patients have a higher risk of thrombotic and ischemic events after percutaneous coronary intervention. JACC Cardiovasc. Interv. 2021; 14 (10): 1094–1105. DOI: 10.1016/j.jcin.2021.03.049
  48. Thomason N., Monlezun D.J., Javaid A. et al. Percutaneous coronary intervention in patients with gynecological cancer: machine learning-augmented propensity score mortality and cost analysis for 383,760 patients. Front. Cardiovasc. Med. 2022; 8: 793877. DOI: 10.3389/fcvm.2021.793877
  49. Chauhan S., Monlezun D.J., Kim J.W. et al. Fractional flow reserve cardio-oncology effects on inpatient mortality, length of stay, and cost based on malignancy type: machine learning supported nationally representative case-control study of 30 million hospitalizations. Medicina (Kaunas). 2022; 58 (7): 859. DOI: 10.3390/medicina58070859
  50. Potts J.E., Iliescu C.A., Lopez Mattei J.C. et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur. Heart J. 2019; 40 (22): 1790–1800. DOI: 10.1093/eurheartj/ehy769
  51. Waqar F., Sultan A., Bathija R.R. et al. Cardiovascular interventions in patients with active and advanced malignancy: an updated review. J. Commun. Hosp. Intern. Med. Perspect. 2024; 14 (4): 34–41. DOI: 10.55729/2000-9666.1369
  52. Valgimigli M., Smits P.C., Frigoli E. et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur. Heart J. 2022; 43 (33): 3100–3114. DOI: 10.1093/eurheartj/ehac284
  53. Mehran R., Cao D., Angiolillo D.J. et al. 3- or 1-Month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. JACC Cardiovasc. Interv. 2021; 14 (17): 1870–1883. DOI: 10.1016/j.jcin.2021.07.016
  54. Ahmed T., Pacha H.M., Addoumieh A. et al. Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents. Front. Cardiovasc. Med. 2022; 9: 901431. DOI: 10.3389/fcvm.2022.901431
  55. Aziz M.K., Herrmann J., Marmagkiolis K. et al. Coronary stent healing in cancer patients – an optical coherence tomography perspective. Front. Cardiovasc. Med. 2021; 8: 665303. DOI: 10.3389/fcvm.2021.665303
  56. Garatti A., D’Ovidio M., Saitto G. et al. Coronary artery bypass grafting in patients with concomitant solid tumours: early and long-term results. Eur. J. Cardiothorac. Surg. 2020; 58 (3): 528–536. DOI: 10.1093/ejcts/ezaa114
  57. Sigaev I.Yu., Keren M.A., Slivneva I.V. et al. The algorithm for using transit-time flow measurement and high-resolution epicardial ultrasound for intraoperative grafts assessment during coronary artery bypass surgery. Kardiologiia. 2022; 62 (8): 3–10 (in Russ). DOI: 10.18087/cardio.2022.8.n1823
  58. Golukhova E.Z., Slivneva I.V., Kozlova O.S. et al. Treatment strategies for chronic coronary heart disease with left ventricular systolic dysfunction or preserved ejection fraction – a systematic review and meta-analysis. Pathophysiology. 2023; 30 (4): 640–658.
  59. Kurchatova O.I., Bockeria L.A., Kudzoeva Z.F. The role of coronary heart disease in the treatment of patients undergoing surgical correction of severe aortic valve stenosis. Grudnaya i Serdechno-Sosudistaya Khirurgiya. 2025; 67 (4): 369–378 (in Russ.). DOI: 10.24022/0236-2791-2025-67-4-369-378

About Authors

  • Olga S. Kozlova, Cand. Med. Sci., Researcher, Head of Outpatient Department, Cardiologist, Ultrasonic Diagnostician; ORCID
  • Inessa V. Slivneva, Cand. Med. Sci., Head of the Cardiac Imaging and Innovative Technologies Group, Ultrasonic Diagnostician; ORCID
  • Andrey L. Pylev, Cand. Med. Sci., Сhief Physician, Oncologist; ORCID
  • Karen V. Petrosyan, Dr. Med. Sci., Professor, Head of Department of X-ray Surgical Diagnostic and Treatment Methods; ORCID
  • Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of the Russian Academy of Sciences, Chief of Chair of Cardiology and Functional Diagnostics with a Course in Pediatric Cardiology, Director; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by